Content
04/03/2024
Watertown, MA USA
Diagonal Therapeutics
completed $128 million Series A Round funding. Investors include
BVF Partners (lead), Atlas Venture (lead), Checkpoint Capital, Frazier Life Sciences, Lightspeed Venture Partners, RA Capital Management, Viking Global Investors.
About
Diagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients including therapies for hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
